Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by ronrydellon Jul 13, 2013 7:54pm

96 Views

Post# 21606194

RE:RE:RE:RE:RE:Publication timeline?

A reasonable post and point made..at least it appears we didn't or aren't going thru a manipulative short like before and maybe we can hold at .80 to $1.20 over the next month. Also what about Zenith..please correct me if I'm wrong but do they have 10MM in assets and 19MM in debt all transferred from RVX prior to the spinoff?

we're in salubrious IPO environment currently!

Bullboard Posts

How one company is disrupting PoC testing